Objective:

To explore the needs and expectations of retina practices from their GPO and specialty distributor amidst rising drug costs and increasing operational complexities, emphasizing the critical nature of these relationships.

Key Findings:

• Practices face challenges with opaque pricing structures and slow rebate payments, impacting their financial health.
• Inefficient drug management leads to excess inventory, operational delays, and increased working capital tied up in unused stock.
• There is a strong demand for strategic guidance and education on drug procurement to navigate the evolving market.
• Trust and long-term partnerships are essential for practices to maintain autonomy and economic sustainability.

Interpretation:

Retina practices require more than just product delivery from their GPO and SD; they seek transparency, flexibility, and innovative solutions to enhance drug management and operational efficiency, reflecting their urgent needs.

Limitations:

• The perspectives shared are anonymized and may not represent all practices, potentially introducing bias.
• The resource does not endorse specific practices or recommendations.

Conclusion:

AllyGPO and BioCareSD aim to provide a supportive partnership focused on transparency, competitive pricing, and innovative technology, helping retina practices thrive while maintaining their autonomy and economic sustainability.